Home / Health / New Bone Health Drugs Launch in US
New Bone Health Drugs Launch in US
7 Apr
Summary
- Bosaya and Aukelso, targeting bone conditions, are now prescribed.
- These biosimilars offer affordable treatment options for patients.
- US sales for denosumab products reached $5 billion in 2024.
Biocon Limited announced the commercial launch of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States on April 7, 2026. These medications are biosimilars to Prolia and Xgeva, respectively, and are now accessible by prescription across the nation. Patients can obtain these treatments through specialty pharmacies and healthcare providers.
The US Food and Drug Administration previously approved both Bosaya and Aukelso, granting them an interchangeable designation in September 2025. This designation permits substitution at the pharmacy level, subject to state regulations. The introduction of these drugs represents a strategic move by Biocon to expand its biosimilars offerings in oncology and immunology.
These denosumab-based therapies are crucial for managing bone health issues, including osteoporosis and bone complications arising from cancer. The significant market demand for accessible treatment options is underscored by the approximately $5 billion in US sales recorded by denosumab products in 2024.
Biocon aims to provide high-quality, affordable treatment alternatives for individuals dealing with serious bone conditions. The company views this launch as a key step in its mission to build a scalable access platform for life-changing medicines globally.
